Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea
Author:
Open Access
- 5 July 2008
- journal article
- review article
- Published by Springer Nature in International Journal of Hematology
- Vol. 88 (1) , 16-23
Abstract
Emerging clinical data indicate that transfusion-dependent patients with bone marrow-failure syndromes (BMFS) are at risk of the consequences of iron overload, including progressive damage to hepatic, endocrine, and cardiac organs. Despite the availability of deferoxamine (DFO) in Korea since 1998, data from patients with myelodysplastic syndromes, aplastic anemia, and other BMFS show significant iron overload and damage to the heart and liver. The recent introduction of deferasirox, a once-daily, oral iron chelator, may improve the availability of iron chelation therapy to iron-overloaded patients, and improve compliance in patients who may otherwise find adherence to the DFO regimen difficult.Keywords
This publication has 41 references indexed in Scilit:
- Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective studyEuropean Journal of Haematology, 2007
- Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantationBlood, 2007
- Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonanceBlood, 2005
- Evaluation of iron overloadBritish Journal of Haematology, 2004
- Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron poolBlood, 2003
- Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndromeLeukemia, 2003
- The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overloadBritish Journal of Haematology, 1996
- Okuläre Nebenwirkung der Deferoxamin-Therapie bei aplastischer Anämie mit transfusionsbedingter HämochromatoseKlinische Monatsblätter für Augenheilkunde, 1996
- DESFERRIOXAMINE TREATMENT REDUCES BLOOD TRANSFUSION REQUIREMENTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMEBritish Journal of Haematology, 1992
- Clinical Consequences of Acquired Transfusional Iron Overload in AdultsNew England Journal of Medicine, 1981